Nusano
  • Company
    • Leadership
    • Mission & Values
    • West Valley City
    • Contact Us
  • Technology
  • Life Sciences
    • Medical Isotopes
    • Request Quote
    • R&D Collaboration
    • Advisory Board
    • About Nuclear Med
  • Energy
    • HALEU
    • Nuclear Fuel Cycle
  • Industrial
  • Batteries
  • News
    • Press Releases
    • Video
    • Podcast
  • Careers
    • Current Openings
    • Life in Utah
Select Page
Nusano Announces Breakthrough HALEU Program Expected to Produce Up to 350 Metric Tons of Fuel Annually for Advanced Nuclear Reactors

Nusano Announces Breakthrough HALEU Program Expected to Produce Up to 350 Metric Tons of Fuel Annually for Advanced Nuclear Reactors

by Scott Larrivee | Jun 11, 2025 | News, Utah

Reservations available now, commercial production deliveries begin Q1 2027 Proprietary process with reduced environmental impacts Efficient domestic supply chain needed to support projected growth in energy demand from increased electrification and energy-intensive...
Nusano Stable Isotope Program Enriches Gadolinium-160 to 99.2% Purity

Nusano Stable Isotope Program Enriches Gadolinium-160 to 99.2% Purity

by Scott Larrivee | Jun 10, 2025 | News

Domestic stable isotope program key to stabilizing supply chains, enabling innovation WEST VALLEY CITY, Utah – June 10, 2025 – Nusano today announced it has successfully enriched gadolinium-160 (Gd-160) to 99.2% purity, a significant milestone demonstrating the...
Talk Radioisotopes: Sigal Kalmanson Cusnir, CEO and Co-Founder, Starget Pharma

Talk Radioisotopes: Sigal Kalmanson Cusnir, CEO and Co-Founder, Starget Pharma

by Scott Larrivee | May 29, 2025 | Podcast

In this episode of Talk Radioisotopes, host Scott Larrivee sits down with Sigal Kalmanson, CEO and Co-Founder of Starget Pharma, an early-stage company at the forefront of precision oncology. Starget is redefining the way radiopharmaceuticals are discovered and...
Talk Radioisotopes: Milton Lönnroth, Co-Founder and CEO, Atley Solutions

Talk Radioisotopes: Milton Lönnroth, Co-Founder and CEO, Atley Solutions

by Scott Larrivee | May 16, 2025 | Podcast

In this episode, Milton Lönnroth, Co-Founder and CEO, shares how Atley Solutions is changing the game for astatine-211, a promising isotope in cancer therapy. Atley supports radiopharmaceutical companies and researchers by enabling the scalable production and labeling...
Registration for 2025 World Astatine Community Meeting Now Open

Registration for 2025 World Astatine Community Meeting Now Open

by Scott Larrivee | May 12, 2025 | News

Radiopharmaceutical experts and researchers to gather June 19-20 in New Orleans NEW ORLEANS – May 12, 2025 – The first-ever U.S.-based meeting of the World Astatine Community will take place June 19-20, 2025 at the Sheraton in downtown New Orleans. The event will...
« Older Entries
Next Entries »

Recent Posts

  • Talk Radioisotopes: Paul Schrimpf, Proprietor & Entrepreneur, Cyrall
  • Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement
  • Nusano CEO Chris Lowe on Connor Group Podcast
  • dGenThera and Nusano Sign Letter of Intent for Astatine‑211 Supply
  • Ratio Therapeutics and Nusano Enter Long-Term, Multi-Isotope Supply Agreement to Boost Production of Cancer Radiopharmaceuticals

Recent Comments

No comments to show.
Nusano
Supplying the fight against cancer & enabling life-changing innovations
  • Follow
  • Follow
  • Follow
Company
about us
Leadership
Contact us
technology

The Nusano Platform
R&D Collaboration

Resources
News
Careers
Suppliers
© 2025 Nusano | Web design
Privacy Policy – Terms of Service